河南太龙药业股份有限公司 2025 年第四次临时股东会会议资料 2025 年 11 月 目 录 | 2025 | 年第四次临时股东会会议须知 2 | | --- | --- | | 2025 | 年第四次临时股东会会议议程 3 | | 议案一 | 关于 2025 年前三季度利润分配方案的议案 4 | | 议案二 | 关于拟申请注册发行中期票据的议案 5 | 1 2025 年第四次临时股东会会议须知 为维护投资者的合法权益，确保本次股东会顺利进行，河南太龙 药业股份有限公司（以下简称"公司"）根据《中华人民共和国公司 法》《上市公司股东会规则》以及《公司章程》等有关规定，制定会 议须知如下： 一、本次股东会设秘书处，负责会议组织工作和处理相关事宜。 二、为保证本次股东会的严肃性和正常秩序，除依法出席会议的 公司股东（或股东代理人）、董事、高级管理人员、聘请的律师及相 关工作人员外，公司有权依法拒绝其他人士入场。 三、出席会议的股东（或股东代理人）必须在会议召开前十分钟 向股东会秘书处办理签到、登记手续。 四、股东（或股东代理人）参加股东会依法享有发言权、质询权、 表决权等权利。股东需要发言或就有关问题进行提问的 ...

Core Viewpoint - Tai Long Pharmaceutical (600222.SH) has completed the sale of all 10.8461 million shares held under its third employee stock ownership plan, which has now been terminated [1] Summary by Relevant Sections - **Employee Stock Ownership Plan** - The third employee stock ownership plan has been fully executed and automatically terminated as of the announcement date [1] - The total number of shares sold under this plan amounts to 10.8461 million [1] - **Asset Management** - All assets held under the employee stock ownership plan are now converted into monetary assets [1] - The company will proceed with the liquidation and distribution of the related assets from the third employee stock ownership plan [1]

Core Viewpoint - Tailong Pharmaceutical (600222.SH) announced the complete sale of 10.8461 million shares held under its third employee stock ownership plan as of the announcement date [1] Group 1 - The third employee stock ownership plan has successfully sold all shares it held [1] - The total number of shares sold amounts to 10.8461 million [1]

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-057 河南太龙药业股份有限公司 关于第三期员工持股计划股票出售完毕暨终止的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南太龙药业股份有限公司（以下简称"公司"）第三期员工持 股计划所持有的公司股票已全部出售完毕，根据《关于上市公司实施 员工持股计划试点的指导意见》《上海证券交易所上市公司自律监管 指引第 1 号——规范运作》及《河南太龙药业股份有限公司第三期员 工持股计划》（以下简称"第三期员工持股计划"）等相关规定，第 三期员工持股计划实施完毕并终止。现将相关情况公告如下： 一、第三期员工持股计划基本情况 证券代码：600222 证券简称：太龙药业 公告编号：临 2025-057 （www.sse.com.cn）披露的临 2022-023 号、临 2022-035 号、临 2022-077 号等相关公告。 2、2022 年 11 月 22 日，公司收到中国证券登记结算有限责任公 司出具的《过户登记确认书》，公司回购专用证券账户中所持有的 10, ...

Core Insights - TaiLong Pharmaceutical (600222.SH) reported a total revenue of 1.187 billion yuan for Q3 2025, ranking 29th among disclosed peers, which is a decrease of 154 million yuan or 11.47% year-on-year [1] - The net profit attributable to shareholders was 25.33 million yuan, ranking 41st among peers, down by 3.57 million yuan or 12.36% compared to the same period last year [1] - The company experienced a net cash outflow from operating activities of 88.99 million yuan, ranking 55th among peers, but this represents an increase of 7.73 million yuan year-on-year [1] Financial Ratios - The latest debt-to-asset ratio is 55.88%, ranking 53rd among peers, which is an increase of 2.12 percentage points from the previous quarter but a decrease of 0.63 percentage points year-on-year [3] - The gross profit margin is 24.29%, ranking 54th among peers, down by 0.40 percentage points from the previous quarter and down by 2.20 percentage points year-on-year [3] - The return on equity (ROE) is 1.59%, ranking 42nd among peers, which is a decrease of 0.25 percentage points compared to the same period last year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share (EPS) is 0.05 yuan, ranking 39th among peers, which is a decrease of 0.01 yuan or 11.75% year-on-year [3] - The total asset turnover ratio is 0.33 times, ranking 32nd among peers, down by 0.04 times year-on-year, representing a decline of 10.57% [3] - The inventory turnover ratio is 2.12 times, ranking 14th among peers, which is an increase of 0.10 times or 5.03% year-on-year [3] Shareholder Structure - The number of shareholders is 40,400, with the top ten shareholders holding 168 million shares, accounting for 29.31% of the total share capital [3] - The largest shareholder is Zhengzhou TaiRong Industrial Investment Co., Ltd., holding 14.37% of the shares [3] - Other notable shareholders include Zhengzhou Zhongsheng Industrial Group Co., Ltd. with 8.71% and Wu Lan with 1.38% [3]

Group 1 - The core viewpoint of the article is that Tailong Pharmaceutical (SH 600222) held its 10th fourth board meeting on October 28, 2025, to discuss the proposal for the fourth extraordinary shareholders' meeting in 2025 [1] - For the first half of 2025, Tailong Pharmaceutical's revenue composition is as follows: 70.59% from pharmaceutical manufacturing, 14.71% from pharmaceutical research and development, 14.42% from pharmaceutical distribution, and 0.28% from other businesses [1] - As of the report date, Tailong Pharmaceutical has a market capitalization of 3.7 billion yuan [1]

Core Viewpoint - Tai Long Pharmaceutical (600222.SH) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The total operating revenue for the first three quarters reached 1.187 billion yuan, a year-on-year decrease of 11.47% [1] - The net profit attributable to shareholders was 25.3255 million yuan, down 12.36% year-on-year [1] - Basic earnings per share were reported at 0.0458 yuan [1] Dividend Announcement - The company plans to distribute a cash dividend of 0.14 yuan (including tax) for every 10 shares to all shareholders [1]

Group 1 - The core point of the article is that Tai Long Pharmaceutical reported its Q3 2025 financial results, showing a revenue increase and a significant rise in net profit [1] Group 2 - In Q3 2025, the company achieved a revenue of 424,470,623.44 yuan, representing a year-on-year growth of 2.67% [1] - The net profit attributable to shareholders of the listed company was 5,978,861.00 yuan, reflecting a substantial year-on-year increase of 162.48% [1]

关于拟申请注册发行中期票据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南太龙药业股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开第十届董事会第四次会议，审议通过了《关于拟申请注 册发行中期票据的议案》。为进一步拓宽融资渠道，增加债务融资的 多样性与灵活性，优化融资结构，根据《公司法》《银行间债券市场 非金融企业债务融资工具管理办法》等相关规定，并结合公司实际情 况，公司拟向中国银行间市场交易商协会（以下简称"交易商协会"） 申请注册发行总额不超过人民币 6 亿元（含）的中期票据，具体情况 如下： 一、本次中期票据发行方案的主要内容 （一）注册和发行规模：拟注册发行规模不超过人民币 6 亿元 （含），具体发行规模将以公司在交易商协会注册的金额为准。 （二）发行期限：不超过 5 年（含）。 （三）发行方式：在批准的注册额度及有效期内一次或分期发行。 （四）资金用途：用于补充营运资金、置换金融机构借款和到期 债务融资工具及交易商协会认可的其他用途。 （五）发行利率：根据发行时银行间债券市场的实际 ...

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-056 河南太龙药业股份有限公司 关于召开 2025 年第三季度业绩 暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 07 日(星期五)11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 31 日（星期五）至 11 月 06 日（星 期四）16:00 期间登录上证路演中心网站首页点击"提问预征集"栏 目 进 行 提 问 ， 或 将 问 题 以 电 子 邮 件 形 式 发 送 至 公 司 邮 箱 600222@taloph.com。公司将在说明会上对投资者普遍关注的问题进 行回答。 河南太龙药业股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司《2025 年第三季度报告》和《2025 年前三季度 利润分配 ...